Hybio Pharmaceutical (300199) - Total Assets
Based on the latest financial reports, Hybio Pharmaceutical (300199) holds total assets worth CN¥3.17 Billion CNY (≈ $463.97 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 300199 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Hybio Pharmaceutical - Total Assets Trend (2007–2024)
This chart illustrates how Hybio Pharmaceutical's total assets have evolved over time, based on quarterly financial data. See Hybio Pharmaceutical shareholders equity for net asset value and shareholders' equity analysis.
Hybio Pharmaceutical - Asset Composition Analysis
Current Asset Composition (December 2024)
Hybio Pharmaceutical's total assets of CN¥3.17 Billion consist of 15.4% current assets and 84.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 3.2% |
| Accounts Receivable | CN¥104.90 Million | 3.5% |
| Inventory | CN¥238.63 Million | 7.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥430.09 Million | 14.3% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2007–2024)
This chart illustrates how Hybio Pharmaceutical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Hybio Pharmaceutical market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hybio Pharmaceutical's current assets represent 15.4% of total assets in 2024, a decrease from 64.1% in 2007.
- Cash Position: Cash and equivalents constituted 3.2% of total assets in 2024, up from 3.1% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 0.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 14.3% of total assets.
Hybio Pharmaceutical Competitors by Total Assets
Key competitors of Hybio Pharmaceutical based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621
|
China | CN¥2.30 Billion |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
China | CN¥8.59 Billion |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
|
China | CN¥925.41 Million |
|
Jw Pharmac
KO:001060
|
Korea | ₩605.27 Billion |
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Samjin Pharm
KO:005500
|
Korea | ₩449.14 Billion |
Hybio Pharmaceutical - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.37 | 0.43 | 0.95 |
| Quick Ratio | 0.18 | 0.23 | 0.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-951.59 Million | CN¥-737.61 Million | CN¥-49.98 Million |
Hybio Pharmaceutical - Advanced Valuation Insights
This section examines the relationship between Hybio Pharmaceutical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 24.90 |
| Latest Market Cap to Assets Ratio | 0.88 |
| Asset Growth Rate (YoY) | -8.2% |
| Total Assets | CN¥3.01 Billion |
| Market Capitalization | $2.64 Billion USD |
Valuation Analysis
Near Book Valuation: The market values Hybio Pharmaceutical's assets close to their book value (0.88x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Hybio Pharmaceutical's assets decreased by 8.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hybio Pharmaceutical (2007–2024)
The table below shows the annual total assets of Hybio Pharmaceutical from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.01 Billion ≈ $440.20 Million |
-8.21% |
| 2023-12-31 | CN¥3.28 Billion ≈ $479.56 Million |
-9.25% |
| 2022-12-31 | CN¥3.61 Billion ≈ $528.44 Million |
-7.56% |
| 2021-12-31 | CN¥3.91 Billion ≈ $571.63 Million |
-2.83% |
| 2020-12-31 | CN¥4.02 Billion ≈ $588.30 Million |
-14.91% |
| 2019-12-31 | CN¥4.72 Billion ≈ $691.38 Million |
-16.53% |
| 2018-12-31 | CN¥5.66 Billion ≈ $828.28 Million |
+6.84% |
| 2017-12-31 | CN¥5.30 Billion ≈ $775.27 Million |
+18.87% |
| 2016-12-31 | CN¥4.46 Billion ≈ $652.20 Million |
+25.69% |
| 2015-12-31 | CN¥3.55 Billion ≈ $518.89 Million |
+108.90% |
| 2014-12-31 | CN¥1.70 Billion ≈ $248.39 Million |
+31.72% |
| 2013-12-31 | CN¥1.29 Billion ≈ $188.58 Million |
+14.71% |
| 2012-12-31 | CN¥1.12 Billion ≈ $164.40 Million |
+8.48% |
| 2011-12-31 | CN¥1.04 Billion ≈ $151.55 Million |
+386.48% |
| 2010-12-31 | CN¥212.89 Million ≈ $31.15 Million |
+16.67% |
| 2009-12-31 | CN¥182.47 Million ≈ $26.70 Million |
+33.63% |
| 2008-12-31 | CN¥136.55 Million ≈ $19.98 Million |
+134.46% |
| 2007-12-31 | CN¥58.24 Million ≈ $8.52 Million |
-- |
About Hybio Pharmaceutical
Hybio Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of peptide and oligonucleotide drugs in China and internationally. The company offers finished dosage form (FDF) products for obstetrics and gynecology, haemostatic agent, digestive tract and metabolic systems, immune system modulation, cardiovascular, diabetes mellitus, and osteoporosis, as well as dis… Read more